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Introduction 
Despite the low prevalence rates (0.5-2%) 1'2 , vascular 
graft infection can be life-threatening and no effort 
should be spared to further research that will have 
direct clinical application. 
Many attempts have been made to include antibiotic 
in graft material in order to provide drug coverage in 
the immediate perioperative period when the graft is 
most likely to become infected by direct contamination 
or blood-borne infection. Richardson et al. 3 attempted 
simple impregnation of the graft with an antibiotic 
solution. This gave the thrust to many other research 
endeavours. The choice of antibiotic has been widely 
studied, with many authors advocating the ef- 
fectiveness of rifampicin. Recently Chervu et al. 4 ob- 
tained encouraging experimental results using a 
solution of collagen and rifampicin to impregnate a
Dacron graft. Goue-Brissoniere etal. 5 and Avramovic 
and Fetcher 6 reported satisfactory prevention of sta- 
phylococcal blood-borne and direct contamination 
using a rifampicin-bonded gelseal graft: this im- 
pregnation method relies on the ionic bond that forms 
between the negatively charged free carboxyl groups 
in the gelatin and the positively charged molecules of 
rifampicin. 
Recently the Centre for the Study of Vascular Pros- 
theses at the University of Bologna has carried out 
experimental research into the use of rifampicin- 
bonded gelseal grafts. An initial study showed that the 
rifampicin remaining attached to the graft implanted in 
the blood stream of experimental animals was suf- 
ficient to inhabit bacterial growth for up to 72 h after 
implantation. 7 A second study demonstrated that the 
antibiotic-bonded graft was effectively protected from 
blood-borne infections. 8 
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These data await further confirmation in clinical 
trials, and the results of two controlled studies are 
now available. 
Materials and Methods 
The first prospective study ran from March 1991 to 
July 1994, and included 600 patients of both sexes and 
all ages, suffering from chronic peripheral obstructive 
arteriopathy and/or aortoiliac aneurysm and who re- 
ceived either an aortomono, bifemoral or iliacfemoral 
vascular graft (Italian Study). 9Patients were randomly 
allocated into two groups: group A received aVascutek 
gelseal graft which had been soaked for 15 min in a 
solution of rifampicin (1 mg/ml of saline) and group 
B, the control group, receiving an untreated Vascutek 
gelseal graft. All patients underwent a subcutaneous 
sensitisation test to ascertain any allergic reaction to 
rifampicin. All patients received prophylactic anti- 
biotic treatment with cephalosporin (cephalothin, ce- 
fazolin, cephamandole) or, if allergic, gentamicin: 
antibiotic overage was started I h before surgery and 
continued for 4 days postoperatively. On entry into 
the study, numerous clinical parameters were assessed 
for subsequent s atistical analysis. Subsequent clinical 
investigations were carried out at 1, 6, 12 and 24 
months. Vascular graft patency, the presence or ab- 
sence of skin infection, fever or inguinal abscess were 
noted. When infection was suspected, researchers were 
asked to follow up with computed tomography (CT)- 
scan, radio-isotope investigations, blood cultures and 
any other examination deemed useful for diagnosis of 
grade 3 graft infection according to the Szilagyi's 
classification. 11 
The second study was performed in several Euro- 
pean countries from September 1991 to September 
1993, with the aim to evaluate, with the same bonding 
protocol, the effectiveness in the prevention of early 
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postoperative wound and graft infection in aorto- 
femoral bypass graft (European study). ~° A total of 
1276 patients enrolled in group A (rifampicin-bonded 
graft) and 1246 in group B (untreated bonded graft). 
Subsequent clinical investigation was carried out at 1 
month to detect early postoperative wound and graft 
infections, according to Szilagyi's classification. 11 
Results 
The analysis of epidemiological factors and of the risk 
of vascular graft infection in the patient population of 
both studies, shows that the groups of patients were 
similar in terms of age, sex and predisposing risk 
factors. 
In the Italian study, during the first year observation 
period, 11 cases of infection (1.8%) were observed: five 
in group A (1.7%) and six in group B (2.0%). This 
difference is not statistically significant. At the second 
year of follow-up one more infection was observed in 
group B. At this time the total infection rate was 2% 
(12/600) and the infection rate in group B was 2.3% 
(7/304). 
Compared to the uninfected patients, infected 
patients showed a significantly higher incidence of 
lymphatic complication, and early revision surgery 
(p=0.005, p=0.001). Except in two cases, the onset 
of infection was always within the first month after 
surgery. Staphylococcus aureus was the most frequently 
isolated pathogen (50%). In three cases the bac- 
teriological report was not available. Diagnosis of in- 
fection was mainly clinical and in only four cases were 
further investigations (CT-Scan, radioactive isotopes) 
carried out. In our view, these examinations would 
have been useful to assess the extent of infection, 
especially in the early onset cases. Infections had to 
fall within grade 3 of Szilagyi's classification. 11 
The European study demonstrated a positive trend 
in group A for the prevention of both superficial 
wound infection (Grade I: 2.3% vs. 3.5%) and deep 
wound infection (Grade II: 0.6% vs. 0.9%). The same 
positive trend was observed for graft involvement 
(Grade III: 0.3% vs. 0.6%). There was a statistical 
difference if Grade I and II wound infections were 
combined (2.9% vs. 4.4, p<0.05 vs. control group). 
literature. 12 Lymphatic complications and early re- 
vision surgery were confirmed as negative prognostic 
factors, and inguinal infection proved to be the primary 
site of infection. 
Experimental data indicate that the antibiotic seems 
to remain active on the graft surface for up to 4 days. 7
Whether this period is sufficient remains in doubt. 
Animal studies have shown that the graft retains 
bactericidal qualities of antibiotics for the first 2 days. 5
If the contamination of the graft occurs within this 
time then an increased protection should be afforded 
against his challenge. If the challenge occurs after this 
time it may be that the antibiotic is not present in 
sufficient quantity to be bactericidal, but is merely 
bacteriostatic. Latent infections can therefore develop 
subsequently. Moreover, this short period provides 
little or no protection against other pathogenetic mech- 
anisms such as late blood borne or lymphatic in- 
fections. 
Some authors have attempted a mix of collagen and 
antibiotic which is then sealed on to the graft material, 
therebody lodging the antibiotic among the fibres of 
the Dacron material. Release of antibiotic into the 
surrounding tissue is thus slower, taking place as the 
collagen is gradually digested by the host enzymes. 
This method has been reported to provide antibiotic 
coverage for up to 21 days. 4'5 In the experimental 
observations, antibiotic activity in the bonded graft is 
limited to only a few days. However, infections are 
known to have very long latency periods and inhibiting 
bacterial growth is not synonymous with bacterial 
death. Moreover, bacteria are known to increase in 
virulence even after months or years in the event of 
lowered host immunity. 
Conclusions 
Both clinical studies howed no statistically significant 
benefit from the clinical use of vascular grafts pre- 
treated with antibiotic for the prevention of graft in- 
fection, but the method showed a positive trend. The 
only significant data concerned the prevention of early 
wound infection. Extending the duration of antibiotic 
at the graft site might be desirable. The use of anti- 
biotic-bonded gelseal grafts would seem especially 
indicated in cases at greater isk for infection, such as 
surgical revision cases. 
Discussion 
The overall infection rate in these clinical studies was 
2%, which is in line with the most recent data in 
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